Use of pattern analysis to predict differential relapse of remitted patients with major depression during 1 year of treatment with fluoxetine or placebo

Archives of General Psychiatry

Volumn 55, Issue 4, 1998, Pages 334-343

  Stewart, Jonathan W ^a,h   Quitkin, Frederic M ^a   McGrath, Patrick J ^a   Amsterdam, Jay ^b   Fava, Maurizio ^c   Fawcett, Jan ^d   Reimherr, Frederick ^e   Roscnbaum, Jerrold ^c   Beasley, Charles ^f   Roback, Paul ^g  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d RUSH UNIVERSITY MEDICAL CENTER   (United States)

^e UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^f ELI LILLY AND COMPANY   (United States)

^g Department of Environmental and Radiological Health Sciences   (United States)

^h Unit 35   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; FLUOXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HAMILTON SCALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MULTICENTER STUDY; PSYCHOPHARMACOTHERAPY; RELAPSE; TREATMENT FAILURE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; DEPRESSIVE DISORDER; DOUBLE-BLIND METHOD; FEMALE; FLUOXETINE; HUMANS; MALE; MIDDLE AGED; PATTERN RECOGNITION, AUTOMATED; PLACEBO EFFECT; PLACEBOS; PROBABILITY; PROGNOSIS; PROSPECTIVE STUDIES; RECURRENCE; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0031945177     PISSN: 0003990X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archpsyc.55.4.334     Document Type: Article

References (25)

1. Stahl S. 5HT1A receptors and pharmacotherapy: is serotonin receptor down-regulation linked to the mechanism of action of antidepressant drugs? Psychopharmacol Bull. 1994;30:39-43.
2. Duncan G, Paul I, Breese G. Neuroanatomical differences on the rate of betaadrenergic receptor adaptation after repeated treatment with imipramine. Psychopharmacol Bull. 1993;29:401-407.
3. Richelson E. Biological basis of depression and therapeutic relevance. J Clin Psychiatry. 1991;52(suppl):4-10.
4. Freo U, Pierini P, Dam M, Pizzolato G, Battistin I. The tricyclic antidepressant clomipramine dose dependently reduces regional cerebra metabolic rates for glucose. Psychopharmacology. 1993;113:53-59.
5. Lucki I. Behavioral studies of serotonin receptor agonists as antidepressant drugs. J Clin Psychiatry. 1991;52(suppl):24-31.
6. Marek C, McDougle L, Price L, Seiden I, A comparison of trazodone and fluoxetine: implications for a serotonergic mechanism of antidepressant action. Psychopharmacology. 1992;109:2-11.
7. Hemrich-Luecke S, Snoddy H, Fuller R. Evaluation of nefazodone as a serotonin uptake Inhibitor and a serotonin antagonist In vivo. Life Sci. 1994;54:479-483.
8. Richelson E. The pharmacology of antidepressants at the synapse: focus on newer compounds. J Clin Psychiatry. 1994;55(suppl A):34-39.
9. Toth M, Shenk T. Antagonist-mediated down-regulation of 5-hydroxytryptamine type 2 receptor gene expression: modulation of transmission. Mol Pharmacol. 1994;45:1095-1100.
10. Stahl S, Hanger R, Rawsch J, Fleischaber J, Hubbell-Alberts E. Down-regulation of serotonin receptor subtypes by nortriptyline and adinazolam in major depressive disorder: neuroendocrine and platelet markers. Clin Neuropharmacol. 1993;16(suppl):S19-S31.
11. Li Q, Levy A, Cabrera T, Brownfield M, Battaglia G, Van de Korl L. Long-term fluoxetine but not desipramine inhibits the ACTH and oxytocin responses to the 5-HT1A agonist8-OH-DPAT in male rats, Brain Res. 1993;630:148-156.
12. Wieland C, Fischette T, Luck I. Effect of chronic treatments with tandospirone and imipramine on serotonin-mediated behavioral responses and monoamine receptors. Neuropharmacology. 1993;32:561-573.
13. 2-adrenoceptors exclusively by sibutramine hydrochlorlde. Psychopharmacology, 1992;107:497-502.
14. Lund A, Mjellem N, Chronic combined treatment with desipramine and mianserin: enhanced 5HT1A receptor function and altered 5-HT1AV5-HT2 receptor interaction in rats, Pharmacol Biochem Behav. 1993;45:777-783.
15. Beasley C, Masica D, Potvin J. Fluoxetine: a review of receptor and functional effects and their clinical implications. Psychopharmacology. 1992;107:1-10.
16. Richelson E. Pharmacology of antidepressants: characteristics of the Ideal drug. Mayo Clin Proc. 1994;69:1069-1081.
17. Brown WA. Placebo as a treatment for depression, Neuropsychopharmacology. 1994;10:265-269.
18. Quitkin F, Rabkin J, Ross D, Stewart JW. Identification of true drug response to antidepressants: use of pattern analysis. Arch Gen Psychiatry, 1984;41:782-786.
19. Quitkin F, Rabkin J, Markowitz J, Stewart JW, McGrath PJ, Harrison W, Use of pattern analysis to identify true drug response: a replication. Arch Gen Psychiatry. 1987;44:259-264.
20. Fieve R. Goodnick P, Peselow E, Barouche F, Schlegel A. Pattern analysis of antidepressant response to fluoxetine. J Clin Psychiatry. 1986;47:560-562.
21. Dunlop S, Dornseif B, Wernicke F, Potvin J. Pattern analysis shows beneficial effect of fluoxetine treatment in mild depression. Psychopharmacol Bull. 1990;26:173-180.
22. American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders, Third Edition, Revised, Washington, DC: American Psychiatric Association; 1987.
23. Hamilton M, A rating scale for depression. J Neural Neurosurg Psychiatry. 1960;23:56-62.
24. McGlashan T, ed. The Documentation of Clinical Psychoiropic Drug Trials. Rockville, Md: National Institute of Mental Health; 1973.
25. Amsterdam JD, Fawcett J, Quitkin FM, Reimherr FW, Rosenbaum JF, Michelson D, Hornig-Rohan M, Beasley CM. Fluoxetine and norfluoxetine plasma concentrations in major depression: a multicenter study. Am J Psychiatry. 1997;154:963-969.